Liu Qiang, Chairman of YaoPharma, said: "By leveraging Pfizer's exceptional global development experience and commercialisation network, along with YaoPharma's profound expertise in small molecule R&D and manufacturing, our shared goal is to accelerate the global development and commercialisation of this innovative drug, thereby benefiting patients worldwide more rapidly and extensively." Pfizers moves with Metsera and now YaoPharma add to continued competition in the obesity drug market, which has also seen Teva Pharmaceuticals gain US Food and Drug Administration (FDA) approval in August of a generic GLP-1 of its version of Novo Nordisks injectable Saxenda (liraglutide).
Funding This work was supported by grants from the National Natural Science Foundation of China (82270390, 81970364, 82170595, 82170436, and 81970070) and the Hubei Province Innovation Platform Construction Project (20204201117303072238)
Many studies support the roles of dietary fiber in preventing the progression and development of prostate cancer
Starting dose, titration, gender-specific protocols, and IGF-1 monitoring
10.1016/j.eplepsyres.2011.05.020 Epilepsy Res